Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

R. Bramhall, S.; Rosemurgy, A.; D. Brown, P.; Bowry, C.; A.C. Buckels, J.; the Marimastat Pancreatic Cancer Study Group, for

doi:10.1200/jco.2001.19.15.3447

Public

Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

Shared by NobleBlocks on Aug 1, 2001 • 12:00 AM UTC

Authors:

S. R. Bramhall

A. Rosemurgy

P. D. Brown

Abstract

PURPOSE: The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic canc...

Discussions